Baricitinib (phosphate)

Baricitinib (phosphate)

• CAS Number: 1187595-84-1
• UNSPSC Description: Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable JAK1/JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, respectively.
• Target Antigen: JAK
• Type: Reference compound
• Related Pathways: Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/Baricitinib-phosphate.html
• Solubility: DMSO : ≥ 4.7 mg/mL
• Smiles: N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(S(=O)(CC)=O)C1.O=P(O)(O)O
• Molecular Weight: 469.41
• References & Citations: [1]Fridman JS, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010 May 1;184(9):5298-307.|[2]Jabbari A, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015 Feb 26;2(4):351-5.bioRxiv. 2020 Oct 5;2020.10.04.325415. |Commun Biol. 2021 Jun 2;4(1):654.|J Clin Invest. 2024 Oct 1;134(19):e176828.|Research Square Preprint. 2020 Dec.|ACS Nano. 2024 Mar 4.|Acta Pharmacol Sin. 2020 Aug 27. |Adv Sci (Weinh). 2020 Sep 24;7(21):2002518.|bioRxiv. 2018 Feb.|bioRxiv. 2020 Jun.|bioRxiv. 2020 Mar.|bioRxiv. 2024 Jul 12:2024.07.11.603146.|bioRxiv. 2024 July 07.|Br J Pharmacol. 2024 Sep 2.|Cancer Res. 2021 Dec 15;81(24):6131-6141.|Cell. 2021 Apr 15;184(8):2167-2182.e22.|Chemrxiv. 2023 Aug 3.|Chemrxiv. Aug 11, 2021.|Diabetologia. 2023 Nov 4.|Eur J Pharm Sci. 2024 Jul 4:106845.|Heliyon. 2018 Nov 26;4(11):e00979. |Inflammation. 2021 Feb;44(1):206-216.|Institute of Natural Medicine,University of Toyama, Japan. 2018, Nov.|Int Immunopharmacol. 2022 Jul 15;110:109044.|Int Immunopharmacol. 2024 Aug 9:140:112894.|Int J Obes (Lond). 2015 Nov;39(11):1607-18. |J Allergy Clin Immunol. 2023 Dec 8:S0091-6749(23)02411-9.|J Autoimmun. 2022 Feb;127:102793.|J Clin Invest. 2021 Dec 15;131(24):e145501.|J Dermatol Sci. 2024 Oct 22.|J Exp Med. 2024 Mar 4;221(3):e20230683.|J Immunol. 2013 Oct 1;191(7):3568-77. |Karolinska Institutet. 2024 May 31.|Mol Syst Biol. 2023 Dec 18.|Nat Commun. 2023 Apr 24;14(1):2342.|Pharmacol Rep. 2024 Aug 19.|Platelets. 2021 Jun 7;1-12.|PLoS One. 2017 Jul 14;12(7):e0181126.|Res Sq. 2024 Jul 16.|Research Square Preprint. 2024 Mar 21.|Rheumatology. 2023 Jan 17;kead013.|RSC Adv. 2018, 8, 21534-21540.|Sci Adv. 2024 Mar 22;10(12):eadl0368.|Sci Immunol. 2024 Jul 12;9(97):eadn0178.|Sci Rep. 2022 May 12;12(1):7843.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Science. 2017 Dec 1;358(6367):eaan4368.|Signal Transduct Target Ther. 2021 Apr 24;6(1):165.|Toxicol Sci. 2020 Aug 1;176(2):410-422.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched